Fundz

Addex Therapeutics Ltd reported raising $4.23 Million in an initial SEC Form D filing, from an offering of $4.23 Million

PUBLIC · ADXNAug 04, 2022

Amount Raised

$4.23 Million

$4.23 Million sold, per SEC Form D (first sale Jul 22, 2022)

Round Type

Seed

SwitzerlandBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as Addex Therapeutics Ltd. that raised within 45 days of this round, from Fundz verified event records.

  • Fresenius Medical Care raised $3.6M on September 2, 2022.
  • Monteris Medical raised $14M on September 2, 2022.
  • Abivax raised $49M (Funding Round) on September 2, 2022.
  • Bekaert raised an undisclosed amount on September 1, 2022.
  • FathomX raised an undisclosed amount (Pre-Series A) on September 1, 2022.
  • Puna Bio raised $3.7M (Seed) on September 1, 2022.

Who to call at Addex Therapeutics Ltd., and when

A new round usually means Addex Therapeutics Ltd. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Addex Therapeutics Ltd. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Addex Therapeutics Ltd., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Addex Therapeutics Ltd.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Addex Therapeutics Ltd.

Location

CHEMIN DES MINES 9

Switzerland

About

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Addex Therapeutics Ltd. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsVincent L., Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Addex Therapeutics Ltd.'s next move

See what Strategic adds

Addex Therapeutics Ltd. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.